ctDNA Molecular Response After Pembrolizumab Treatment in Patients With NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results
Nat. Med. 2023 Oct 01;29(10)2559-2569, V Anagnostou, C Ho, G Nicholas, RA Juergens, A Sacher, AS Fung, P Wheatley-Price, SA Laurie, B Levy, JR Brahmer, A Balan, N Niknafs, E Avrutin, L Zhu, M Sausen, PA Bradbury, J O'Donnell-Tormey, PO Gaudreau, K Ding, J DanceyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.